FDA approves revised medication guide for Coumadin

Share this article:
The FDA has approved a revised medication guide and labeling for Bristol-Myers Squibb's blood thinner Coumadin (warfarin sodium) to more prominently emphasize a warning about the risk of major or fatal bleeding.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.